Notable Labs

Notable Labs OCF Margin

The Operating Cash Flow Margin of Notable Labs (NTBLQ) as of Nov 11, 2026 is -4,424.52 %. In the previous year, Operating Cash Flow Margin was -4,786.36 % — a change of -7.56% (higher).

OCF Margin

-4,424.52 %

YoY

-7.56%

Last updated:

Operating Cash Flow Margin of Notable Labs is 2023 -4,424.52 % . Operating Cash Flow Margin of Notable Labs was 2022 -4,786.36 % . It decreases by -7.56% higher compared to the previous year.

The Notable Labs OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2017
-27.56 USD
Jan 1, 2018
-2,657.63 USD
Jan 1, 2019
-2,337.50 USD
Jan 1, 2020
-2,541.30 USD
Jan 1, 2021
-3,244.16 USD
Jan 1, 2022
-4,786.36 USD
Jan 1, 2023
-4,424.52 USD
The Notable Labs OCF Margin history
YEAROCF MarginYoY
-4,424.52 %-7.56%
-4,786.36 %+47.54%
-3,244.16 %+27.66%
-2,541.30 %+8.72%
-2,337.50 %-12.05%
-2,657.63 %+9,542.59%
-27.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

Operating Cash Flow Margin of Notable Labs is -4,424.52 % in 2023.

Operating Cash Flow Margin of Notable Labs changed from -4,786.36 % to -4,424.52 %, representing a -7.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Notable Labs since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Notable Labs with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Notable Labs

All Key Metrics — Notable Labs